(BVS) Bioventus - Overview
Stock: Injectables, Stimulators, Bone Grafts, Ultrasonic
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 59.3% |
| Relative Tail Risk | -13.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.23 |
| Alpha | -37.71 |
| Character TTM | |
|---|---|
| Beta | 0.920 |
| Beta Downside | 1.140 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.20% |
| CAGR/Max DD | 1.14 |
Description: BVS Bioventus December 28, 2025
Bioventus Inc. (NASDAQ:BVS) is a Durham-based medical-device firm that markets a broad suite of musculoskeletal and pain-management solutions. Its portfolio spans intra-articular and hyaluronic-acid injections (e.g., Durolane, GELSYN-3, SUPARTZ) for knee osteoarthritis, peripheral-nerve stimulation systems (Stimrouter, Talisman), precision ultrasonic surgical platforms (Nexus, BoneScalpel, SonaStar), and a range of bone-graft and fracture-repair products (Osteoamp, Signafuse, Purebone, Reficio, Exogen). The company also offers minimally invasive spine and fracture-rehabilitation therapies, positioning itself across the full continuum of orthopedic and neurosurgical care.
Key recent metrics: • FY 2023 revenue was approximately $312 million, up ~4% YoY, driven primarily by growth in the hyaluronic-acid injection line. • The cash-and-cash-equivalents balance stood at $115 million at year-end, providing runway for R&D and potential strategic acquisitions. • The U.S. musculoskeletal device market is projected to expand at a 5% CAGR through 2028, supported by an aging population and increasing prevalence of osteoarthritis, while reimbursement pressures remain a sector-wide headwind.
If you want a data-rich, analyst-level perspective on BVS’s valuation and risk profile, a quick look at ValueRay’s platform can be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 7.82m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.85 > 1.0 |
| NWC/Revenue: 21.13% < 20% (prev 15.71%; Δ 5.42% < -1%) |
| CFO/TA 0.08 > 3% & CFO 56.0m > Net Income 7.82m |
| Net Debt (280.4m) to EBITDA (89.7m): 3.13 < 3 |
| Current Ratio: 1.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.8m) vs 12m ago 5.48% < -2% |
| Gross Margin: 67.51% > 18% (prev 0.67%; Δ 6684 % > 0.5%) |
| Asset Turnover: 76.65% > 50% (prev 72.13%; Δ 4.52% > 0%) |
| Interest Coverage Ratio: 1.39 > 6 (EBITDA TTM 89.7m / Interest Expense TTM 30.2m) |
Altman Z'' -0.87
| A: 0.17 (Total Current Assets 280.9m - Total Current Liabilities 161.8m) / Total Assets 701.6m |
| B: -0.50 (Retained Earnings -349.7m / Total Assets 701.6m) |
| C: 0.06 (EBIT TTM 42.0m / Avg Total Assets 735.5m) |
| D: -0.71 (Book Value of Equity -351.4m / Total Liabilities 494.3m) |
| Altman-Z'' Score: -0.87 = CCC |
Beneish M -3.05
| DSRI: 1.05 (Receivables 130.4m/121.9m, Revenue 563.8m/555.1m) |
| GMI: 0.99 (GM 67.51% / 67.00%) |
| AQI: 1.00 (AQ_t 0.56 / AQ_t-1 0.56) |
| SGI: 1.02 (Revenue 563.8m / 555.1m) |
| TATA: -0.07 (NI 7.82m - CFO 56.0m) / TA 701.6m) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of BVS shares?
Over the past week, the price has changed by +7.31%, over one month by +11.24%, over three months by +13.77% and over the past year by -21.49%.
Is BVS a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BVS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15 | 76.3% |
| Analysts Target Price | 15 | 76.3% |
| ValueRay Target Price | 7.2 | -15% |
BVS Fundamental Data Overview February 05, 2026
P/E Forward = 10.0705
P/S = 0.9788
P/B = 3.3308
P/EG = 2.1421
Revenue TTM = 563.8m USD
EBIT TTM = 42.0m USD
EBITDA TTM = 89.7m USD
Long Term Debt = 311.3m USD (from longTermDebt, last quarter)
Short Term Debt = 11.2m USD (from shortTermDebt, last quarter)
Debt = 322.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 280.4m USD (from netDebt column, last quarter)
Enterprise Value = 832.3m USD (551.9m + Debt 322.6m - CCE 42.2m)
Interest Coverage Ratio = 1.39 (Ebit TTM 42.0m / Interest Expense TTM 30.2m)
EV/FCF = 15.57x (Enterprise Value 832.3m / FCF TTM 53.5m)
FCF Yield = 6.42% (FCF TTM 53.5m / Enterprise Value 832.3m)
FCF Margin = 9.48% (FCF TTM 53.5m / Revenue TTM 563.8m)
Net Margin = 1.39% (Net Income TTM 7.82m / Revenue TTM 563.8m)
Gross Margin = 67.51% ((Revenue TTM 563.8m - Cost of Revenue TTM 183.2m) / Revenue TTM)
Gross Margin QoQ = 66.95% (prev 69.14%)
Tobins Q-Ratio = 1.19 (Enterprise Value 832.3m / Total Assets 701.6m)
Interest Expense / Debt = 1.91% (Interest Expense 6.18m / Debt 322.6m)
Taxrate = 14.22% (664.0k / 4.67m)
NOPAT = 36.0m (EBIT 42.0m * (1 - 14.22%))
Current Ratio = 1.74 (Total Current Assets 280.9m / Total Current Liabilities 161.8m)
Debt / Equity = 1.94 (Debt 322.6m / totalStockholderEquity, last quarter 166.1m)
Debt / EBITDA = 3.13 (Net Debt 280.4m / EBITDA 89.7m)
Debt / FCF = 5.24 (Net Debt 280.4m / FCF TTM 53.5m)
Total Stockholder Equity = 155.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.06% (Net Income 7.82m / Total Assets 701.6m)
RoE = 5.02% (Net Income TTM 7.82m / Total Stockholder Equity 155.9m)
RoCE = 8.98% (EBIT 42.0m / Capital Employed (Equity 155.9m + L.T.Debt 311.3m))
RoIC = 7.32% (NOPAT 36.0m / Invested Capital 492.2m)
WACC = 6.48% (E(551.9m)/V(874.5m) * Re(9.31%) + D(322.6m)/V(874.5m) * Rd(1.91%) * (1-Tc(0.14)))
Discount Rate = 9.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.52%
[DCF Debug] Terminal Value 77.69% ; FCFF base≈43.7m ; Y1≈28.7m ; Y5≈13.1m
Fair Price DCF = 1.09 (EV 353.6m - Net Debt 280.4m = Equity 73.2m / Shares 67.0m; r=6.48% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 27.86 | EPS CAGR: -3.65% | SUE: -3.18 | # QB: 0
Revenue Correlation: 50.23 | Revenue CAGR: 1.65% | SUE: 0.09 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.12 | Chg30d=-0.005 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.80 | Chg30d=-0.015 | Revisions Net=-1 | Growth EPS=+20.4% | Growth Revenue=+7.1%